24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825
Fax: (361)578-5500

Medical Disorders
Resources
Basic InformationLookupsLatest News
Could the Pill Reduce Asthma Attacks?Coronavirus Most Contagious Soon After InfectionPeople Should Know That COVID Vaccine Might Spur Transient Sickness: CDC ExpertsAnother Study Finds COVID Usually Mild in KidsBlacks, Hispanics Account for More Than Half of COVID Deaths: StudyCollege Kid Coming Home for Thanksgiving? Here's How to Keep Your Family SafeParents' Age Key to Whether Kids Get Vaccinated Against COVID, Study FindsVegan Diets Tied to Higher Bone Fracture RiskThird COVID Vaccine Shows Effectiveness; FDA Approves New TreatmentWhich Kids With COVID Will Get Very Sick?Add Kids to COVID Vaccine Trials, Pediatricians' Group SaysLosing Your Hair Because of Pandemic Stress?How Hospitals Can Cut Patients' FallsMany Young Americans Lonely, Depressed During Pandemic: SurveyWHO Says No to Remdesivir as COVID-19 TreatmentBirx Says U.S. COVID Cases Are Skyrocketing as Holidays ApproachA 'Stunning' Alternative Rx for Arthritic Joints?Are Statin Side Effects 'All in Your Head'?Stay Home This Holiday, CDC and Medical Groups UrgeDirty Air Endangers Homeless People: StudyU.S. Coronavirus Deaths Top a Quarter MillionOxford COVID Vaccine Safe, Effective, Especially in Older AdultsAre High-Dose Blood Thinners Needed for Severe COVID-19?Childhood Lead Exposure Tied to Brain Changes in Middle AgeWith Cold Weather Forcing Patrons Inside, How Safe Are Restaurants?AHA News: Fauci Offers a COVID-19 Lesson and Looks to the Future'A Struggle:' Physical, Mental Ills Can Linger Months After COVID RecoveryExoskeleton Helps Paralyzed People Walk AgainAre You Feeling 'Pandemic Fatigue'?Chinese COVID Vaccine Appears Safe, EffectiveFDA Approves First Rapid COVID Test for Home UseCould Night Shifts Raise Asthma Risk?AHA News: Black, Hispanic People Hospitalized for COVID-19 at Disproportionately High RatesAHA News: COVID-19 Patients of All Ages With Obesity Face Higher Risk of Complications, DeathOverweight With Arthritic Knees? You Might Want to Avoid TennisAnswers to Your Questions About Face MasksHow to Be a Living Liver DonorCoronavirus Immunity Might Last at Least 6 MonthsCalifornia, Iowa Toughen Restrictions as COVID Cases ClimbAllergies Won't Up Your Odds for Severe COVIDCombo 'Polypill' May Cut Heart Attack, Stroke Risk Up to 40%Restful Sleep Could Help Ward Off Heart FailureMany Americans Plan to Party Indoors, Regardless of Risk: SurveyDeadly New Ebola-Like Disease Emerges in BoliviaModerna Vaccine Shows 94.5% Effectiveness Against COVIDGlobal Warming Has Ticks Jumping From Dogs to HumansMore Evidence That Vaping Ups Lung Disease RiskAHA News: Heart Risk Factors Vary Greatly Among Asian ImmigrantsWrongly Prescribing Antibiotics Sets Dangerous PatternLarge Study Finds Blacks, Asians More Vulnerable to COVID
Questions and AnswersLinks
Related Topics

Diabetes

WHO Says No to Remdesivir as COVID-19 Treatment

HealthDay News
by Robert Preidt
Updated: Nov 20th 2020

new article illustration

FRIDAY, Nov. 20, 2020 (HealthDay News) -- The antiviral drug remdesivir is not recommended for hospitalized COVID-19 patients because there's no evidence that it reduces their need for ventilation or improves their chances of survival, a World Health Organization panel said Thursday.

Remdesivir is regarded as a potential treatment for severe COVID-19 and is used to treat hospitalized patients, but there is uncertainty about its effectiveness. Nevertheless, the U.S. Food and Drug Administration approved the drug to treat hospitalized COVID-19 patients in October.

In the new assessment, the WHO panel of experts analyzed data from four international randomized trials that assessed several treatments for COVID-19 and included more than 7,000 hospitalized COVID-19 patients.

The panel -- which included four people who've had COVID-19 -- concluded that remdesivir has no meaningful impact on the risk of death or any other important patient outcomes, such as the need for mechanical ventilation or how long it takes for their condition to improve.

The results of the trials don't prove that remdesivir has no benefit. Instead, they provide no evidence that the drug improves patient outcomes, the panel explained in an article published Nov. 19 in the BMJ medical journal.

However, given the risk of significant harm, the relatively high cost, and the demands on health care staff (remdesivir must be given intravenously), their recommendation is appropriate, the panel said.

The panel also said they support continued enrollment into trials evaluating the use of remdesivir in COVID-19 patients, especially to provide more reliable evidence for specific groups of patients.

The future use of remdesivir in treating COVID-19 patients is unclear, given that it's unlikely to be the lifesaving drug many have hoped for, American journalist Jeremy Hsu wrote in a linked article in the journal.

He also noted that alternative treatments -- such as the inexpensive and widely available corticosteroid dexamethasone, which has been shown to reduce death risk in severely ill COVID-19 patients -- are now part of the discussions about remdesivir's worth as a COVID-19 treatment.

"It's become clear that remdesivir, at best, has a marginal benefit if any on clinical improvement," said Dr. Amesh Adalja, a senior scholar at the Johns Hopkins Center for Health Security in Baltimore. "It is not surprising, therefore, that the WHO guideline committee does not support its use, underscoring the need for better treatments that more meaningfully impact patient outcomes."

More information

For more on treatments for severe COVID-19, go to the U.S. Centers for Disease Control and Prevention.


SOURCES: BMJ, news release, Nov. 19, 2020; Amesh Adalja, MD, senior scholar, Johns Hopkins Center for Health Security, Baltimore